Indivior, a world leader in addiction treatments, makes Montreal its new home in Canada

Global pharmaceutical company relocates from Ottawa to Montreal to take advantage of world-class expertise and facilities in dynamic pharmaceutical industry hub, to continue its growth and development of addiction treatments, including for opioid addictions

MONTREAL, Feb. 22, 2018 /CNW/ - Montreal is now the home of a world leader in the development of new evidence-based treatment models for addiction with the opening by Indivior Canada Ltd. of its new Canadian headquarters.

The new offices of the specialty pharmaceutical company are in Technoparc Montréal in the St-Laurent Borough of the City of Montreal after moving from Ottawa, where the company started operations in Canada several years ago.

A team of 25 Indivior employees are based at or report to the new office. With a commitment to honesty and integrity and a patient-centred approach, the team will focus on bringing to Canadians the company's unique evidence-based treatment models that have revolutionized addiction treatment.

"We are thrilled to now be operating from Montreal, which we chose because of its dynamic biopharmaceutical sector, pool of qualified bilingual talent, and world-class expertise and facilities focused on learning about and treating addiction as a medical condition like other chronic diseases," said Christine LaFave, Country Director, Indivior Canada Ltd. "Indivior is focused exclusively on the increasingly vital work of helping Canadian physicians treat opioid addiction as a chronic illness, and improving access to treatments for patients – helping them overcome addiction and get back on the path to leading healthy and productive lives."

Indivior Canada markets SUBOXONE® (buprenorphine and naloxone) sublingual tablets for the treatment of problematic opioid drug dependence in adults. Indivior has a 20-year legacy of leadership in the field of evidence-based addiction therapies and is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease.

It adopted the name Indivior – a fusion of the words individual and endeavour – in 2014 when it became an independent entity following the demerger of Reckitt Benckiser Pharmaceuticals Inc. from RB Group. Headquartered in Richmond, Virginia, Indivior employs more than 900 individuals globally and its portfolio of products is available in over 40 countries worldwide.

Building on its portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia.

For more information about Indivior, visit Indivior.com.

SOURCE Indivior Canada Ltd.

Rose Marie Barone, Indivior Canada Ltd., Tel: [phone], [email protected]